Francesco Rodeghiero

Francesco Rodeghiero's AcademicInfluence.com Rankings

Computer Science

#5180

World Rank

#5474

Historical Rank

Machine Learning

#1276

World Rank

#1296

Historical Rank

Artificial Intelligence

#1506

World Rank

#1535

Historical Rank

Database

#2327

World Rank

#2442

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Francesco Rodeghiero's Degrees

PhD Computer Science University of Milan
Masters Computer Science University of Milan
Bachelors Computer Science University of Milan

Similar Degrees You Can Earn

Why Is Francesco Rodeghiero Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Francesco Rodeghiero's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. (2009) (2167)
International consensus report on the investigation and management of primary immune thrombocytopenia. (2010) (1778)
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. (2005) (1195)
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor (2006) (1060)
Epidemiological investigation of the prevalence of von Willebrand's disease. (1987) (942)
Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. (1995) (790)
Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. (2000) (616)
ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders (2010) (565)
A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1 VWD) (2006) (509)
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study (2013) (506)
Impact, Diagnosis and Treatment of von Willebrand Disease (2000) (497)
Molecular Remission in PML/RARα-Positive Acute Promyelocytic Leukemia by Combined All-trans Retinoic Acid and Idarubicin (AIDA) Therapy (1997) (488)
Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. (1990) (448)
Updated international consensus report on the investigation and management of primary immune thrombocytopenia. (2019) (432)
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). (2012) (424)
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. (2011) (415)
Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). (2007) (384)
Romiplostim or standard of care in patients with immune thrombocytopenia. (2010) (365)
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. (2011) (365)
Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. (2004) (358)
Acquired von Willebrand Syndrome: Data from an International Registry (2000) (346)
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments (2008) (325)
The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study (2005) (324)
Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. (2009) (272)
Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. (2004) (267)
Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. (2007) (261)
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. (2014) (253)
The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. (2009) (238)
Activated Protein C Resistance and Factor V Leiden Mutation Are Independent Risk Factors for Venous Thromboembolism (1999) (235)
Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. (1990) (234)
Congenital absence of the inferior vena cava: a rare risk factor for idiopathic deep-vein thrombosis (2001) (229)
A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. (2012) (227)
Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. (1997) (224)
Adult height and the risk of cause-specific death and vascular morbidity in 1 million people: individual participant meta-analysis. (2012) (220)
Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. (2003) (210)
Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long‐term follow‐up of a randomized clinical trial (2000) (209)
Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. (2008) (192)
Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin's lymphoma in adults. (2004) (188)
Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. (2013) (185)
Validated questionnaire for the identification of previous personal or familial venous thromboembolism. (1996) (181)
Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. (2013) (178)
Thrombopoietin receptor agonists: ten years later (2019) (166)
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia (2015) (165)
Clinical Manifestations and Management of Inherited Thrombophilia: Retrospective Analysis and Follow-up after Diagnosis of 238 Patients with Congenital Deficiency of Antithrombin III, Protein C, Protein S (1994) (161)
Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM‐1VWD) (2008) (160)
Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). (2008) (159)
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases (2007) (155)
Rabbit antithymocyte globulin (r‐ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy (1999) (147)
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria (2012) (139)
Platelet lysate as a substitute for animal serum for the ex-vivo expansion of mesenchymal stem/stromal cells: present and future (2016) (139)
Early haemorrhagic morbidity and mortality during remission induction with or without all‐trans retinoic acid in acute promyelocytic leukaemia (2000) (130)
Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. (1992) (129)
Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group (2011) (129)
Provisional criteria for the diagnosis of VWD type 1: on behalf of the ISTH SSC Subcommittee on von Willebrand Factor (2005) (127)
Different bleeding risk in type 2A and 2M von Willebrand disease: a 2‐year prospective study in 107 patients (2012) (123)
Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation (2011) (119)
von Willebrand disease "Vicenza" with larger-than-normal (supranormal) von Willebrand factor multimers. (1988) (119)
Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD (2006) (117)
Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. (2008) (116)
The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. (2014) (116)
Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. (2008) (115)
Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. (2008) (110)
Interleukin-15 triggers the proliferation and cytotoxicity of granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes. (1997) (110)
Hydroxyurea‐related toxicity in 3,411 patients with Ph'‐negative MPN (2012) (109)
Thrombosis associated with angiogenesis inhibitors. (2009) (104)
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. (2014) (103)
Inconsistency of Association between Type 1 von Willebrand Disease Phenotype and Genotype in Families Identified in an Epidemiological Investigation (1999) (103)
Characterization of the Genetic Defects in Recessive Type 1 and Type 3 von Willebrand Disease Patients of Italian Origin (1998) (102)
Short‐ and long‐term risks of splenectomy for benign haematological disorders: should we revisit the indications? (2012) (101)
Side effects of anti-angiogenic drugs. (2012) (100)
Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years (2013) (98)
Characterization of a novel bleeding disorder with isolated prolonged bleeding time and deficiency of platelet microvesicle generation (1997) (97)
VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. (2013) (94)
Is ITP a thrombophilic disorder? (2016) (93)
Interleukin-15 promotes the growth of leukemic cells of patients with B-cell chronic lymphoproliferative disorders. (1996) (93)
Prospective Multicenter Study on Subcutaneous Concentrated Desmopressin for Home Treatment of Patients with von Willebrand Disease and Mild or Moderate Hemophilia A (1996) (92)
How I treat von Willebrand disease. (2009) (91)
Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A. (1989) (91)
How to estimate bleeding risk in mild bleeding disorders (2007) (91)
Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. (1993) (91)
Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study. (2012) (91)
Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. (2006) (88)
Long‐term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials (2013) (87)
Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery (1993) (87)
Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia (2002) (86)
Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment‐related risk factors (2014) (84)
The VITA Project: C677T mutation in the methylene‐tetrahydrofolate reductase gene and risk of venous thromboembolism (1997) (83)
ETRO Working Party on Factor XIII questionnaire on congenital factor XIII deficiency in Europe: status and perspectives. Study Group. (1996) (80)
Replacement Therapy with Virus—Inactivated Plasma Concentrates in von Willebrand Disease (1992) (77)
Bleeding scores in inherited bleeding disorders: clinical or research tools? (2008) (77)
Clinical indications for desmopressin (DDAVP) in congenital and acquired von Willebrand disease. (1991) (76)
Identification and characterization of a novel P2Y 12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study. (2009) (76)
Von Willebrand Disease Type 2M “Vicenza” in Italian and German Patients: Identification of the First Candidate Mutation (G3864A; R1205H) in 8 Families (2000) (76)
Treatment of elderly patients (≥60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols (2003) (73)
Hepatocellular carcinoma in hemophilia (1991) (73)
Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study (2006) (73)
The Rate of Progression to Polycythemia Vera or Essential Thrombocythemia in Patients with Erythrocytosis or Thrombocytosis (2003) (72)
Additional genetic risk factors for venous thromboembolismin carriers of the factor V Leiden mutation (1998) (71)
Thalidomide and Thrombosis (2003) (70)
Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach. (2008) (70)
Assessing bleeding in von Willebrand disease with bleeding score. (2007) (69)
Pharmacokinetics of Monoclonally-Purified and Recombinant Factor VIII in Patients with Severe von Willebrand Disease (1993) (68)
Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM‐1VWD study (2009) (66)
Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia (1984) (65)
Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V Leiden) and His1299Arg substitutions in factor V (1997) (64)
Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. (2012) (64)
Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1VWD) (2007) (64)
Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. (2010) (63)
Deep intronic variations may cause mild hemophilia A (2011) (63)
Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. (2003) (63)
Autoimmune cytopenias in chronic lymphocytic leukemia (2014) (62)
Hemostatic complications of angiogenesis inhibitors in cancer patients (2008) (62)
The European Hematology Association Roadmap for European Hematology Research: a consensus document. (2016) (62)
Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from a systematic review of the literature (2008) (62)
The epidemiology of inherited thrombophilia: the VITA Project. Vicenza Thrombophilia and Atherosclerosis Project. (1997) (62)
von Willebrand disease: still an intriguing disorder in the era of molecular medicine (2002) (61)
Prolonged overall survival with second on‐demand autologous transplant in multiple myeloma (2006) (61)
Epidermal growth factor, basic fibroblast growth factor and platelet-derived growth factor-bb can substitute for fetal bovine serum and compete with human platelet-rich plasma in the ex vivo expansion of mesenchymal stromal cells derived from adipose tissue. (2011) (60)
Front-Line Treatment of Acute Promyelocytic Leukemia with AIDA Induction Followed by Risk-Adapted Consolidation: Results of the AIDA-2000 Trial of the Italian GIMEMA Group. (2004) (59)
Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon-11 NPM1 mutation (2007) (59)
Molecular and phenotypic determinants of the response to desmopressin in adult patients with mild hemophilia A (2009) (58)
Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia. (1984) (58)
Collaborative meta-analysis of prospective studies of plasma fibrinogen and cardiovascular disease (2004) (57)
Bleeders, bleeding rates, and bleeding score (2013) (57)
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia (2009) (57)
Factor VIII: C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease (1995) (56)
Prognostic significance of CD56 antigen expression in acute myeloid leukemia. (2002) (56)
A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. (2020) (55)
Type I factor XIII deficiency is caused by a genetic defect of its b subunit: insertion of triplet AAC in exon III leads to premature termination in the second Sushi domain. (1996) (54)
Fibrinogen assays: a collaborative study of six different methods. C.I.S.M.E.L. Comitato Italiano per la Standardizzazione dei Metodi in Ematologia e Laboratorio. (1991) (54)
Systematically missing confounders in individual participant data meta-analysis of observational cohort studies (2009) (54)
Prevalence and risk factors of non‐fatal venous thromboembolism in the active population of the VITA Project (2003) (53)
Production of human platelet lysate by use of ultrasound for ex vivo expansion of human bone marrow-derived mesenchymal stromal cells. (2013) (53)
A Standard Nomenclature for von Willebrand Factor Gene Mutations and Polymorphisms (2001) (53)
Pregnancy and delivery in women with von Willebrand’s disease and different von Willebrand factor mutations (2010) (52)
The VITA Project: Population-based Distributions of Protein C, Antithrombin III, Heparin-cofactor II and Plasminogen -Relationship with Physiological Variables and Establishment of Reference Ranges (1996) (51)
Leukocytosis as an important risk factor for arterial thrombosis in WHO‐defined early/prefibrotic myelofibrosis: An international study of 264 patients (2012) (51)
Laboratory issues in bleeding disorders (2006) (51)
A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP (2018) (50)
The VITA Project: Prothrombin G20210A Mutation and Venous Thromboembolism in the General Population (1999) (50)
Age‐adjusted reference limits for carotid intima‐media thickness as better indicator of vascular risk: population‐based estimates from the VITA project (2005) (48)
Congenital von Willebrand disease type I: definition, phenotypes, clinical and laboratory assessment. (2001) (48)
Autosomal dominant type 1 von Willebrand disease due to G3639T mutation (C1130F) in exon 26 of von Willebrand factor gene: description of five Italian families and evidence for a founder effect (2000) (48)
Homocysteine levels in polycythaemia vera and essential thrombocythaemia (1999) (47)
Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide (2006) (47)
Is splenectomy still the gold standard for the treatment of chronic ITP? (2008) (46)
Generation of mesenchymal stromal cells from cord blood: evaluation of in vitro quality parameters prior to clinical use (2017) (46)
The VITA Project: Phenotypic Resistance to Activated Protein C and FV Leiden Mutation in the General Population (1997) (46)
Characterization of two cases of acquired transitory von willebrand syndrome with ciprofloxacin: Evidence for heightened proteolysis of von willebrand factor (1995) (44)
Low prevalence of thrombophilia coagulation defects in patients with deep vein thrombosis of the upper limbs (1997) (44)
Age-adapted moderate-dose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia. (1996) (43)
Assessment of the risk of bleeding in patients undergoing surgery or invasive procedures: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). (2009) (43)
The role of platelet von Willebrand factor in platelet adhesion and thrombus formation: a study of 34 patients with various subtypes of type I von Willebrand disease (1994) (43)
Idiopathic thrombocytopenic purpura: an old disease revisited in the era of evidence-based medicine. (2003) (43)
Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance (2011) (43)
Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia (2017) (43)
The impact of bleeding history, von Willebrand factor and PFA–100® on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM‐1VWD (2010) (42)
Treatment of von Willebrand disease. (2005) (42)
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation (2010) (42)
Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies (2019) (42)
ITP and international guidelines: what do we know, what do we need? (2014) (42)
Reduced von Willebrand factor survival in von Willebrand disease: pathophysiologic and clinical relevance (2009) (41)
A bleeding disorder characterised by isolated deficiency of platelet microvesicle generation (1996) (41)
Fatal pulmonary embolism and antithrombin III deficiency in adult lymphoblastic leukaemia during L-asparaginase therapy. (1983) (41)
An Additional Unique Candidate Mutation (G2470A; M740I) in the Original Families with von Willebrand Disease Type 2 M Vicenza and the G3864A (R1205H) Mutation (2000) (40)
Epidemiology of von Willebrand disease in developing countries. (2005) (40)
Effectiveness of high‐dose intravenous immunoglobulin in a case of acquired von willebrand syndrome with chronic melena not responsive to desmopressin and factor VIII concentrate (1992) (40)
Von Willebrand Factor Antigen Is Less Sensitive than Ristocetin Cofactor for the Diagnosis of Type I von Willebrand Disease -Results Based on an Epidemiological Investigation (1990) (40)
Clinical usefulness of desmopressin for prevention of surgical bleeding in patients with symptomatic heterozygous factor XI deficiency (1996) (39)
Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia (2016) (39)
Mobilization and collection of PBSC in healthy donors: a retrospective analysis of the Italian Bone Marrow Transplantation Group (GITMO). (1997) (39)
Hyper‐responsiveness to DDAVP for patients with type I von Willebrand's disease and normal intra‐platelet von Willebrand factor (1988) (39)
Platelet von willebrand factor abnormalities in myeloproliferative syndromes (1995) (39)
Hematologic malignancies and thrombosis. (2012) (38)
Molecular mechanisms of type II factor XIII deficiency: novel Gly562-Arg mutation and C-terminal truncation of the A subunit cause factor XIII deficiency as characterized in a mammalian expression system. (1998) (38)
Hepatitis B vaccination of 113 hemophiliacs: Lower antibody response in anti‐LAV/HTLV‐III‐positive patients (1986) (38)
Health‐related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease (2016) (38)
A novel candidate mutation (Arg611→ His) in type I‘platelet discordant’von Willebrand's disease with desmopressin‐induced thrombocytopenia (1995) (37)
Gestational thrombocytopenia: a prospective study. (1997) (37)
Effect of platelet lysate on the functional and molecular characteristics of mesenchymal stem cells isolated from adipose tissue. (2011) (37)
Diagnosis of APC Resistance in Patients on Oral Anticoagulant Therapy (1995) (37)
Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins. Results in 17 patients. Italian Cooperative Group for TTP. (1995) (37)
Aberrant cytoplasmic expression of C-terminal-truncated NPM leukaemic mutant is dictated by tryptophans loss and a new NES motif (2007) (36)
Heterogeneous phenotypes of platelet and plasma von Willebrand factor in obligatory heterozygotes for severe von Willebrand disease. (1989) (36)
Thrombotic complications during L-asparaginase treatment for acute lymphocytic leukemia. (1990) (35)
Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report (2019) (35)
Topologically equivalent mutations causing dysfunctional coagulation factors VII (294Ala-->Val) and X (334Ser-->Pro). (1994) (35)
Mutation pattern in clinically asymptomatic coagulation factor VII deficiency (1996) (35)
First‐line therapies for immune thrombocytopenic purpura: re‐evaluating the need to treat (2008) (34)
Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status (2010) (34)
DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma (2001) (34)
Successful pregnancy in a woman with congenital factor XIII deficiency treated with substitutive therapy (1987) (34)
Acquired haemophilia: experience of two Italian centres with 17 new cases (1997) (34)
Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact. (2010) (33)
High levels of histidine-rich glycoprotein and thrombotic diathesis. Report of two unrelated families. (1993) (33)
Un-mutated IgVH in chronic lymphocytic leukemia is associated with a higher risk of immune thrombocytopenia (2007) (32)
Thrombopoietin receptor agonists in hereditary thrombocytopenias (2018) (32)
ABO-incompatible bone marrow transplantation: a GITMO survey of current practice in Italy and comparison with the literature (2004) (32)
Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors (2011) (32)
Treatment of immune thrombocytopenia in adults: the role of thrombopoietin-receptor agonists. (2015) (32)
Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists (2017) (31)
Twenty years experience with treatment of idiopathic thrombocytopenic purpura in a single department: results in 490 cases. (1993) (31)
The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. (2012) (30)
Subunits A and S Inheritance in Four Families with Congenital Factor XIII Deficiency (1978) (30)
Granulocyte colony-stimulating factor (G-CSF, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukaemia: effects, role of patient pretreatment characteristics, and costs. (1997) (30)
Obstetric complications and pregnancy-related venous thromboembolism: The effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation (2012) (30)
The pathophysiology and treatment of hemorrhagic syndrome of acute promyelocytic leukemia. (1994) (30)
Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia (2014) (30)
Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H‐M740I) defect (2006) (29)
A comparative prospective observational study of children and adults with immune thrombocytopenia: 2‐year follow‐up (2018) (29)
Clinical pharmacokinetics of a placenta‐derived factor XIII concentrate in type I and type II factor XIII deficiency (1991) (29)
Acquired transitory von Willebrand syndrome with ciprofloxacin (1994) (29)
Isolated erythrocytosis: study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene (2012) (29)
Mutations in the thrombomodulin gene are rare in patients with severe thrombophilia (2002) (29)
A follow-up study of 49 adult patients with idiopathic thrombocytopenic purpura treated with high-dose immunoglobulins and anti-D immunoglobulins. (1992) (29)
Polycythemia vera and essential thrombocythemia in young patients. (1993) (29)
Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers (2018) (28)
High-throughput immunophenotypic characterization of bone marrow- and cord blood-derived mesenchymal stromal cells reveals common and differentially expressed markers: identification of angiotensin-converting enzyme (CD143) as a marker differentially expressed between adult and perinatal tissue sour (2018) (28)
B‐cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia (2013) (28)
B‐cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities (2014) (28)
Treatment practices in adults with chronic immune thrombocytopenia – a European perspective (2010) (28)
Fibrinopeptide A changes during remission induction treatment with L-asparaginase in acute lymphoblastic leukemia: evidence for activation of blood coagulation. (1990) (28)
Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. (2004) (27)
NON-A, NON-B HEPATITIS AFTER FACTOR VIII CONCENTRATE TREATED BY HEATING AND CHLOROFORM (1985) (27)
Fulminant sepsis in adults splenectomized for idiopathic thrombocytopenic purpura. (1992) (27)
von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels (2010) (27)
An acquired hemorrhagic disorder of fibrin crosslinking due to LgG antibodies to FXIII, successfully treated with FXIII replacement and cyclophosphamide (1995) (27)
Management of menorrhagia in women with inherited bleeding disorders: general principles and use of desmopressin (2007) (27)
Platelet von Willebrand factor assay: results using two methods for platelet lysis. (1990) (26)
Phenotypic APC Resistance in Carriers of the A20210 Prothrombin Mutation Is Associated with an Increased Risk of Venous Thrombosis (2001) (26)
Desmopressin and type II B von Willebrand disease (1996) (26)
Old and new prognostic factors in acute myeloid leukemia with deranged core‐binding factor beta (2013) (26)
Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD. (2010) (26)
Immune thrombocytopenia in lymphoproliferative disorders. (2009) (26)
The bleeding time in normal subjects is mainly determined by platelet von Willebrand factor and is independent from blood group. (1992) (26)
Acquired plasma factor XIII deficiencies. (1993) (26)
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting (2018) (25)
Immunoelectrophoretic evidence of a thrombin‐induced abnormality in a new variant of hereditary dysfunctional antithrombin III (AT III ‘Vicenza’) (1983) (25)
Pregnancy in Women with Type 1 von Willebrand Disease Caused by Heterozygosity for von Willebrand Factor Mutation C1130F (2000) (25)
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia (2012) (24)
Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies. (1997) (24)
ITP and thrombosis: an intriguing association. (2017) (24)
F8 mRNA studies in haemophilia A patients with different splice site mutations (2010) (23)
Association of factor V deficiency with factor V HR2. (2004) (23)
Optimizing treatment of von Willebrand disease by using phenotypic and molecular data. (2009) (23)
Severe spontaneous arterial thrombotic manifestations in patients with inherited hypo‐ and afibrinogenemia (2009) (23)
Epidemiology of hemophilia and of HIV infection in Italy. GICC. Gruppo Italiano Coagulopatie Congenite. (1994) (22)
Multimeric pattern of plasma and platelet von willebrand factor is normal in uremic patients (1993) (22)
Homozygous type 2N R854W von Willebrand factor is poorly secreted and causes a severe von Willebrand disease phenotype (2010) (21)
Isolated erythrocytosis in V617F negative patients with JAK2 exon 12 mutations: Report of a new mutation (2009) (21)
Inherited abnormalities of blood coagulation in juvenile stroke. A case‐control study (1997) (21)
Subunit A of Factor XIII Regulates Subunit B Plasma Concentration (1981) (21)
Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell lines (2012) (21)
Treatment of idiopathic thrombocytopenic purpura (ITP) in patients with refractoriness to or with contraindication for corticosteroids and/or splenectomy with immunosuppressive therapy and danazol. (1993) (21)
Alterations of mRNA processing and stability as a pathogenic mechanism in von Willebrand factor quantitative deficiencies (2010) (21)
Congenital afibrinogenemia: Successful prevention of recurrent hemoperitoneum during ovulation by oral contraceptive (1995) (21)
Therapeutic impact of adult-type acute lymphoblastic leukemia regimens in B-cell/L3 acute leukemia and advanced-stage Burkitt's lymphoma. (1996) (21)
Spectrum of mutations in Albanian patients with haemophilia A: identification of ten novel mutations in the factor VIII gene (2007) (20)
Heterogeneity of Activated Protein C Resistance Phenotype in Subjects with Compound Heterozygosity for HR2 Haplotype and FV Leiden Mutation (R506Q) in Factor V Gene (2000) (20)
Low‐dose alemtuzumab‐associated immune thrombocytopenia in chronic lymphocytic leukemia (2012) (20)
Thrombosis in Subjects with Homozygous and Heterozygous Factor XII Deficiency (1992) (20)
Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper (2019) (20)
Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival (2015) (20)
Acute renal failure after high-dose intravenous immune globulin in a patient with idiopathic thrombocytopenic purpura. (1993) (20)
The VITA Project: Heritability of Resistance to Activated Protein C (2000) (19)
The elusive pathogenesis of von Willebrand disease Vicenza. (2002) (19)
A comparison between two semi‐quantitative bleeding scales for the diagnosis and assessment of bleeding severity in type 1 von Willebrand disease (2011) (19)
Survival and Risk of Leukemic transformation in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study on 1,104 Patients (2010) (19)
The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high‐risk patients with chronic lymphocytic leukemia (2013) (19)
Fibrinolytic studies in 13 unrelated families with factor XII deficiency. (1991) (18)
Fluorescent polymerase chain reaction and capillary electrophoresis for IgH rearrangement and minimal residual disease evaluation in multiple myeloma. (2002) (18)
Sustained Hemostatic Platelet Counts in Adults with Immune Thrombocytopenia (ITP) Following Cessation of Treatment with the TPO Receptor Agonist Romiplostim: Report of 9 Cases, (2011) (18)
Reduced von Willebrand factor secretion is associated with loss of Weibel–Palade body formation (2012) (18)
Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO‐criteria and stratified by calendar period of diagnosis (2015) (18)
Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C? (2014) (18)
High-dose dexamethasone in adult refractory idiopathic thrombocytopenic purpura. (1996) (18)
Erwinia- and E. coli-derived L-asparaginase have similar effects on hemostasis. Pilot study in 10 patients with acute lymphoblastic leukemia. (1993) (18)
Recommended Abbreviations for von Willebrand Factor and Its Activities (2001) (18)
Von Willebrand Disease: Epidemiology (2007) (17)
Disseminated Intravascular Coagulation After Infusion of FEIBA (Factor VIII Inhibitor Bypassing Activity) in a Patient with Acquired Haemophilia (1982) (17)
Symptomatic type II protein C deficiency caused by a missense mutation (Gly 381 → Ser) in the substrate‐binding pocket (1993) (17)
Molecular bases of CRM+ factor X deficiency: a frequent mutation (Ser334Pro) in the catalytic domain and a substitution (Glul02Lys) in the second EGF‐like domain (1995) (17)
Management of immune thrombocytopenia in women: current standards and special considerations (2020) (17)
Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International Study (2011) (17)
Loss of the JAK2 intramolecular auto‐inhibition mechanism is predicted by structural modelling of a novel exon 12 insertion mutation in a case of idiopathic erythrocytosis (2008) (17)
Pregnancy and delivery in patients with homozygous or heterozygous R854Q type 2N von Willebrand disease (2005) (17)
A novel family with recessive von Willebrand disease due to compound heterozygosity for a splice site mutation and a missense mutation in the von Willebrand factor gene. (2002) (16)
Health Related Quality of Life of Long-Term Survivors of Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Chemotherapy (2016) (16)
Identification and characterization of a novel P 2 Y 12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1 VWD study (2009) (16)
A (15;17) translocation not associated with acute promyelocytic leukaemia (1996) (16)
Fibrin glue from single‐donation autologous plasmapheresis (1992) (16)
Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice (2013) (16)
Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: A critical appraisal from literature analysis (2006) (16)
Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia (2013) (16)
Molecular Subunits and Transamidase Activity of Factor XIII During Disseminated Intravascular Coagulation in Acute Leukaemia (1980) (16)
VON WILLEBRAND FACTOR ABNORMALITIES IN TWO PATIENTS WITH URAEMIA (1988) (16)
Analysis of the oxygen sensing pathway genes in familial chronic myeloproliferative neoplasms and identification of a novel EGLN1 germ‐line mutation (2011) (15)
Evidence and Clinical Judgment: Vena cava filters (2014) (15)
Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study. (2019) (15)
Desmopressin‐induced thrombocytopenia in type i platelet discordant von willebrand disease (1993) (15)
The A20210 allele in the prothrombin gene enhances the risk of venous thrombosis in carriers of inherited protein S deficiency (2000) (14)
Hereditary Dysfunctional Antithrombin III (AT-III Vicenza) (1981) (14)
Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis (1999) (14)
Relevance of quantitative assessment of bleeding in haemorrhagic disorders (2008) (14)
Association of plasma fibrinogen, C-reactive protein and G-455>A polymorphism with early atherosclerosis in the VITA Project cohort (2010) (14)
Evans syndrome secondary to chronic lymphocytic leukaemia: presentation, treatment, and outcome (2016) (14)
EDTA‐dependent pseudothrombocytopenia (1992) (14)
Thrombotic risk in patients with immune haemolytic anaemia (2016) (14)
Heightened proteolysis of the von Willebrand factor subunit in patients with von Willebrand disease hemizygous or homozygous for the C2362F mutation (2000) (13)
Chronic immune thrombocytopenic purpura (2009) (13)
A Phase II Study of the HDAC Inhibitor Givinostat In Combination with Hydroxyurea In Patients with Polycythemia Vera Resistant to Hydroxyurea Monotherapy (2011) (13)
Autosomal recessive von Willebrand disease associated with compound heterozygosity for a novel nonsense mutation (2908 del C) and the missense mutation C2362F: Definite evidence for the non‐penetrance of the C2362F mutation (2007) (13)
A new variant of von Willebrand disease (type II I) with a normal degree of proteolytic cleavage of von Willebrand factor. (1992) (13)
Intraindividual consistency of the activated protein C resistance phenotype (2004) (13)
Treatment of hemophilia. (1985) (13)
Some Remarks on the Epidemiology of Thrombotic Disorders (1993) (13)
Eltrombopag second‐line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off‐treatment: results of a phase II, multicentre, prospective study (2021) (13)
Long-lasting remission after high-dose intravenous immunoglobulins in a case of relapsing thrombotic thrombocytopenic purpura. (1991) (13)
Blood group significantly influences von Willebrand factor increase and half‐life after desmopressin in von Willebrand disease Vicenza (2010) (12)
Immunophenotypic and genotypic characterization of B-cell chronic lymphocytic leukemia patients from northern Italy. (1993) (12)
Consistency of responses to separate desmopressin infusions in patients with storage pool disease and isolated prolonged bleeding time. (1993) (12)
High-dose treatment with autologous bone marrow support as consolidation of first remission in younger patients with acute myelogenous leukaemia. (2000) (12)
Bβ 14 Arg→Cys variant dysfibrinogen and its association with thrombosis (2005) (12)
Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia (2018) (12)
Two dimensional immunoelectrophoresis of antithrombin III during disseminated intravascular coagulation in acute leukemia. (1978) (11)
Practical Recommendations for the Management of Patients with ITP During the COVID-19 Pandemic (2021) (11)
Advances in the diagnosis and management of type 1 von Willebrand disease (2011) (11)
Family History And Inherited Thrombophilia (1995) (11)
Effect of the VWF promoter (GT)n repeat and single‐nucleotide polymorphism c.‐2527G>A on circulating von Willebrand factor levels under normal conditions (2011) (11)
Von Willebrand disease: pathogenesis and management. (2013) (11)
Failure of repeated courses of high-dose intravenous immunoglobulin to induce stable remission in patients with chronic idiopathic thrombocytopenic purpura (1995) (11)
Real-world use of thrombopoietin receptor agonists in elderly patients with primary immune thrombocytopenia. (2021) (11)
Results From a Phase IV Open-Label Study Evaluating Changes In Bone Marrow Morphology In Adult Immune Thrombocytopenia (ITP) Patients Receiving Romiplostim: Analysis Of The 1- and 2-Year Romiplostim Cohorts (2013) (10)
Platelet Cut-Off For Anticoagulant Therapy In Cancer Patients With Venous Thromboembolism and Thrombocytopenia: An Expert Opinion Based On RAND/UCLA Appropriateness Method (RAM) (2013) (10)
A study on mutual interaction between cytokine induced killer cells and umbilical cord-derived mesenchymal cells: Implication for their in-vivo use. (2012) (10)
Safety and efficacy of self‐administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials (2020) (10)
The Genetic Defect of Type I von Willebrand Disease “Vicenza” Is Linked to the von Willebrand Factor Gene (1993) (10)
Rituximab, Bendamustine and Cytarabine (R-BAC) Is a Very Active Regimen In Patients with Mantle Cell Lymphoma Not Eligible for Intensive Chemotherapy or Autologous Transplant (2011) (10)
Incidence and Determinants of Bleeding in Different Types of von Willebrand Disease: Results of the First Prospective Multicenter Study on 814 Italian Patients. (2007) (10)
Multiplex Amplification and Fluorimetric Detection of Short Tandem Repeats for Mixed Chimerism After Bone Marrow Transplant (2003) (10)
A comparative evaluation of gene transfer into blood cells using the same retroviral backbone for independent expression of the EGFP and deltaLNGFR marker genes. (2000) (9)
A new Italian family with severe prekallikrein deficiency. Desmopressin-induced fibrinolysis and coagulation changes in homozygous and heterozygous members (1990) (9)
Multivariate statistical data analysis as a tool to analyze ex vivo expansion dynamics of cytokine‐induced killer cells (2013) (9)
Thrombosis in Patients with Heterozygous and Homozygous Factor XII Deficiency Is not Explained by the Associated Presence of Factor V Leiden (1996) (9)
Clinical effectiveness of desmopressin in a case of acquired von Willebrand's syndrome associated with benign monoclonal gammopathy (1989) (9)
Response:Immune thrombocytopenic purpura: terminology and definitions (2009) (9)
Failure of DDAVP to shorten the prolonged bleeding time of two patients with congenital afibrinogenemia. (1992) (9)
Molecular characterization of five Italian families with inherited severe factor XIII deficiency (2007) (9)
Is ticlopidine a safe alternative to aspirin for management of myeloproliferative disorders? (1993) (9)
Treatment of acute lymphoblastic leukemia in adults (1985) (9)
Congenital hypofibrinogenemia associated with novel heterozygous fibrinogen Bβ and γ chain mutations (2008) (9)
Autosomal Recessive von Willebrand Disease Type 1 or 2 due to Homozygous or Compound Heterozygous Mutations in the von Willebrand Factor Gene (2009) (8)
Erythema multiforme after intravenous immunoglobulin (1988) (8)
Fifth Åland Island conference on von Willebrand disease (2018) (8)
Erythroleukaemia, diabetes insipidus and hypophyseal damage: Two case reports. (2007) (8)
Further evidence of heterogeneity of gene defects in Italian families with factor XIII deficiency (2012) (8)
von Willebrand factor multimers von Willebrand disease "Vicenza" with larger-than-normal (supranormal) (2011) (8)
Paroxysmal nocturnal hemoglobinuria (PNH) in the eculizumab era: The bedside and beyond. (2008) (8)
Angiodysplasia and von Willebrand’s Disease (1994) (8)
A contribution to the pathology of acquired plasma factor XIII deficiency. (1985) (8)
Pulmonary embolism after pregnancy in a patient with polycythemia vera (2001) (8)
Hyperuricemic syndromes : pathophysiology and therapy (2004) (8)
Fibrin cross-linking in congenital factor XIII deficiency. (1980) (8)
Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia (2020) (8)
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years. (2019) (8)
Calibration of Lyophilized Standards for Ristocetin Cofactor Activity of von Willebrand Factor (vWF) Requires vWF-Deficient Plasma as Diluent for Dose-Response Curves (1987) (7)
Treatment outcome in a cohort of young patients with polycythemia vera (2010) (7)
Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up. (2009) (7)
Association of Platelet Thromboxane Inhibition by Low‐Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia (2021) (7)
Recurrent thrombosis in patients with polycythemia vera or essential thrombocythemia : efficacy of treatment in preventing rethrombosis in different clinical settings (2006) (7)
Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia. (1998) (7)
International survey on Helicobacter pylori testing in patients with immune thrombocytopenia: Communication of the platelet immunology scientific and standardization committee (2020) (7)
Adult patients with the nephrotic syndrome: really at high risk for deep venous thromboembolism? Report of a series and review of the literature. (1993) (7)
Ifosfamide in Hematological Malignancies of Adults (2003) (7)
A new enemy is emerging in the fight against the SARS-CoV-2 pandemic (2021) (7)
Low risk of venous thrombosis in two families with combined type I plasminogen deficiency and factor V R506Q mutation (1998) (7)
The Epidemiology of von Willebrand Disease (2011) (7)
The coagulopathy of acute promyelocytic leukemia. (2001) (7)
P-310 Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: Results of a prospective, randomized trial (2013) (7)
Flow cytometry in the diagnosis of drug‐induced thrombocytopenia: Two illustrative cases (2008) (6)
Identical IGHV‐D‐J gene rearrangement may precede the clinical onset of chronic lymphocytic leukemia by several years (2010) (6)
Absence of micronucleus formation in CHO-K1 cells cultivated in platelet lysate enriched medium. (2014) (6)
In vivo experiments indicate that relatively high platelet deposition in von Willebrand's disease 'Vicenza' is caused by normal platelet-VWF levels rather than by high VWF-multimers in plasma. (1992) (6)
Fibrinogen Vicenza and Genova II: Two New Cases of Congenital Dysfibrinogenemia with Isolated Defect of Fibrin Monomer Polymerization and Inhibitory Activity on Normal Coagulation (1987) (6)
Prevalence and prognostic impact of KIT mutations in acute myeloid leukaemia with inv(16). A retrospective study (2007) (6)
Economic assessment of eltrombopag in the treatment of thrombocytopenia (2015) (6)
Comparison of low molecular weight heparin CY 216 and unfractionated heparin in preventing post-operative venous thromboembolism in general surgery: a preliminary results of a cooperative study (1990) (6)
Detection of identical T‐cell clonotype expansions in both the donor and recipient after allogeneic bone marrow transplantation (1999) (6)
Acquired transitory factor XI inhibitor after gynaecological surgery (2008) (6)
The management of ‘low‐risk’ and ‘intermediate‐risk’ patients with primary thrombocythaemia (1999) (6)
Heterogeneity of Specific CD4+ and CD8+ T Cells Stimulated by CMV pp65 and IE1 Antigens (2016) (6)
Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients (2005) (6)
First Italian Families with Homozygous R854Q Type 2 N Von Willebrand Disease (2002) (6)
PREGNANCY IN WOMEN WITH ESSENTIAL THROMBOCYTHAEMIA (1996) (5)
Fulminant sepsis in adults splenectomized for Hodgkin's disease. (1993) (5)
Low Prevalence of JAK2 Val617Phe Mutation in Patients with Idiopathic Erythrocytosis. (2005) (5)
The Effects of Romiplostim or Standard of Care (SOC) on Splenectomy and Treatment Failure of Patients Who Had Immune Thrombocytopenia (ITP) for Less Than or Equal to One Year. (2010) (5)
The cytotoxic action of the CD56+ fraction of cytokine-induced killer cells against a K562 cell line is mainly restricted to the natural killer cell subset. (2017) (5)
Von Willebrand disease (2014) (5)
Supranormal antithrombin III levels induced by concentrate administration are ineffective in quenching thrombin generation in acute promyelocytic leukemia. (1993) (5)
Severe factor XI deficiency in the Abruzzo region of Italy is associated to different FXI gene mutations (2008) (5)
Extensive variability in platelet, bleeding, and QOL outcome measures in adult and pediatric ITP: Communication from the ISTH SSC subcommittee on platelet immunology (2021) (5)
B-Cell Receptor Configuration and Adverse Cytogenetics Are Associated with Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia (2012) (5)
Effectiveness of lenalidomide in a patient with refractory anemia with ring sideroblasts and thrombocytosis with JAK2 (V617F) mutation (2015) (5)
Grossly Abnormal Proteolysis of von Willebrand Factor (VWF) in a Patient Heterozygous for a Gene Deletion and Mutation in the Dimerization Area of VWF (2000) (5)
Mortality from myelodysplastic syndromes: A multiple causes of death approach (2014) (5)
Diagnosing type 1 von Willebrand disease: good for patient's health or for doctor's prestige? (2014) (5)
The Aspirin Tolerance Test in von Willebrand’s Disease (1977) (5)
TPO‐receptor agonists in ITP: A clinician's navigation between scylla and charybdis (2012) (5)
Effect of DCEP Mobilizing Regimen in in vivo Purging of PBSC Harvests in Multiple Myeloma (2004) (4)
Factor XI gene mutations in factor XI deficient patients of the Czech Republic (2008) (4)
A new TMHA‐DHPLC assay for the rapid mutation screening of JAK2 exon 14 in myeloproliferative disorders (2008) (4)
[Prevention of hemorrhage and dental treatment of patients with congenital or acquired coagulopathies]. (1997) (4)
Recurrence of the ‘deep-intronic’ FGG IVS6-320A>T mutation causing quantitative fibrinogen deficiency in the Italian population of Veneto (2009) (4)
The von Willebrand factor (1990) (4)
Successful treatment of neonatal "autoimmune" thrombocytopenia with high-dose intravenous immunoglobulins. (1985) (4)
Enumeration of residual white blood cells in leukoreduced blood products: Comparing flow cytometry with a portable microscopic cell counter. (2016) (4)
Factor-XIII subunits-A and -S in congenital deficiency and in acute myeloblastic leukemia. (1974) (4)
The clinical significance of the antiplatelet antibody test based on results for 265 thrombocytopenic patients. (1993) (4)
An unusually prolonged case of heparin-induced thrombocytopenia and disseminated intravascular coagulation. (1992) (4)
Defective Fibrin Crosslinking in Acute Leukemia (1984) (4)
Myeloblative therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia – very long follow‐up (2014) (4)
Triton X contaminating platelet lysate critically affects the measurement of von Willebrand factor ristocetin cofactor activity. (1989) (4)
Subunit Composition of Plasma von Willebrand Factor (vWF) in Two Uremic Patients with Acquired vWF Abnormalities (1992) (4)
The European Survey on Adult’s Evans Syndrome: Analysis of 54 Cases. (2005) (3)
One Year Follow-Up Study of T-Cell Subsets and Incidence of Seropositivity for HTLV-I and HTLV-III Antibodies in Patients Treated “On Demand” or Sporadically with Clotting Concentrates (1985) (3)
The Epidemiology of lnherited Thrombophilia: the VITA Project (1997) (3)
Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A (1989) (3)
Influence of Cholesterol, Triglycerides and Fibrinogen on AT III, PC, HC-II and Plasminogen Measurement (1997) (3)
ERYTHROCYTE FRAGMENTATION IN DISSEMINATED INTRAVASCULAR COAGULATION (DIC) IN ACUTE LEUKAEMIA (1985) (3)
Progressive multifocal leuconcephalopathy and autoimmune haemolytic anemia in chronic lymphocytic leukaemia: more than a fortuitous combination? (2009) (3)
The Coagulopathy of Acute Leukemia (1992) (3)
Clinical significance of LAIR 1 ( CD 305 ) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia (2014) (3)
First Italian family with abnormal antithrombin III (an-III vicenza). (1981) (3)
Single step immunophenotyping of acute leukemias not classifiable by standard morphology and cytochemistry: a practical approach. (1993) (3)
A Prospective Evaluation of Bleeding Tendency and Efficacy of Antihemorrhagic Treatments in Patients with Increased Von Willebrand Factor (VWF) Clearance (Von Willebrand Disease Vicenza AND C1130F Mutation). (2008) (3)
Chapter 6. Von Willebrand Disease (2007) (3)
Parallel line bioassay or single-point calibration for the establishment of reference ranges. (1994) (3)
Recurrent life-threatening epistaxis in a child with Bernard-Soulier syndrome controlled by bilateral ligation of external carotids and ethmoidal arteries. (1987) (3)
The Ser460Pro substitution of the protein S (PS) gene in rare in Italian patients with type IIa PS deficiency. (1996) (3)
Thrombopoietin receptor agonist in chemotherapy-induced thrombocytopenia. (2022) (3)
FACTOR XIII SUBUNIT B DEFICIENCY (1990) (3)
No Influence of Blood Group on the Responsiveness to Desmopressin in Type I “Platelet Normal” von Willebrand’s Disease (1995) (2)
Platelet ristocetin cofactor (RiCof) in patients with type I "platelet normal" von Willebrand disease correlates with plasma RiCof peak after desmopressin infusion. (1995) (2)
Thrombotic and Hemorrhagic Complications after Surgery in Patients with Essential Thrombocythemia and Polycythemia Vera. (2006) (2)
Risk Factors for Thromboembolism (1999) (2)
Parallel line bioassay in a coagulation laboratory. A program for personal computer use and an example application to Ristocetin Cofactor assay. (2008) (2)
Intracellular Retention, Enhanced Clearance, and Defective FVIII Binding Are Common Features of Von Willebrand Factor D9-D3 Domain Mutations in Patients with Von Willebrand Disease Type 1 From the European Mcmdm-1VWD Study (2012) (2)
Final Results from a Phase 4 Open-Label 3-Year Study Evaluating Changes in Bone Marrow (Bm) Morphology in Adult Immune Thrombocytopenia (ITP) Patients (Pts) Receiving the Thrombopoietin Mimetic Romiplostim (2014) (2)
Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia (2018) (2)
A novel heterozygous missense mutation (His127Arg) in a family with inherited cross-reacting material positive factor XI deficiency (2013) (2)
Histidine-rich glycoprotein changes during pregnancy in a woman with genetically transmitted high levels of the protein and thrombotic diathesis. (1993) (2)
Retrospective analysis of treatment of acute myeloblastic leukemia in patients more than 55 years old. (1982) (2)
Microheterogeneity of antithrombin III: effect of single amino acid substitutions and relationship with functional abnormalities (1994) (2)
First-line Idiopathic Thrombocytopenic Purpura Therapies – Benefits and Limitations (2007) (2)
A PROGNOSTIC MODEL to PREDICT SURVIVAL In WHO-DEFINED ESSENTIAL THROMBOCYTHEMIA: A STUDY by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) (2011) (2)
Haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura in southern Iran (2006) (2)
Increased proteolysis of antithrombin III Vicenza during disseminated intravascular coagulation in acute leukemia. (1989) (2)
Acute promyelocytic leukaemia long-term survivors: higher fatigue and greater overall symptom burden (2020) (2)
Evaluation of lymphocytes inactivation by extracorporeal photopheresis using tetrazolium salt based-assay. (2015) (1)
Targeting the Endothelium in Cancer : Clinical Implications (2003) (1)
Efficacy and Safety of Primary Antithrombotic Prophylaxis with Ticlopidine and with Aspirin In Patients with Essential Thrombocythemia and Polycythemia Vera. Results from a Cohort Study. (2008) (1)
Cord Blood-Derived Mesenchymal Stromal Cells for the Treatment of Graft-Versus Host Disease Following Hematological Stem Cell Transplantation (2016) (1)
Risk factors for elastic transformation in myelofibrosis with myeloid metaplasia (MMM) (1995) (1)
Use and positioning of fostamatinib in the management of primary chronic immune thrombocytopenia: an Italian expert opinion (2023) (1)
A new case of passovoy defect (1992) (1)
Fibrinogen survival and fibrinopeptide A in acute leukemia. (1993) (1)
C ombined MV-trans Retinoic Acid and Idarubicin (AIDA) Therapy (1997) (1)
[Therapy with high-dose intravenous gamma globulin in the newborn infant with thrombocytopenia from passive immunization]. (1985) (1)
Investigation of the Role of Copy Number Variation In the Pathogenesis of Type 1 Von Willebrand Disease (2010) (1)
Diagnosing type 1 von Willebrand disease: good for patient's health or for doctor's prestige?: reply (2014) (1)
Clinical significance of fibrinopeptide A in acute lymphocytic and non-lymphocytic leukaemia (1989) (1)
Hematologic and cytogenetic analyses of 99 cases of de novo myelodysplastic syndromes. (1993) (1)
treated by eculizumab patients mechanism of disease in paroxysmal nocturnal hemoglobinuria Complement fraction 3 binding on erythrocytes as additional (2013) (1)
Extensive Variability in Platelet Count, Bleeding, and Quality of Life Outcome Measures in Adult and Pediatric Immune Thrombocytopenia: An Appraisal from a Critical Review of the Literature (2020) (1)
Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: Results of a Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV) (2022) (1)
The Incidence of Chronic Lymphocytic Leukemia in the General Population. (2004) (1)
an Italian retrospective study mutations in core binding factor leukemias: c-KIT Prognostic impact of (2012) (1)
A hit to current “hit” wisdom: A century later, it's time for a change (2017) (1)
Current Management of von Willebrand’s Disease (1995) (1)
A novel fibrinogen gamma chain mutation (gamma 239 Gln-->His) is the cause of dysfibrinogenemia Vicenza. (2005) (1)
A novel fibrinogen γ chain mutation (γ 239 Gln→His) is the cause of dysfibrinogenemia Vicenza (2005) (1)
Younger age at diagnosis of acute promyelocytic leukaemia is associated with better long‐term cognitive functioning (2020) (1)
Management of Spontaneous Bleeding and Prevention of Bleeding After Dental Extractions and Other Surgical Procedures in Mild Hemophilia a and Von Willebrand’s Disease: Ten Years of Experience at the Vicenza Hemophilia and Thrombosis Center (1993) (1)
ON THE DISCREPANT POST‐DDAVP INCREASE OF FVIII:C AND VON WILLEBRAND FACTOR IN SOME PATIENTS WITH SEVERE VON WILLEBRAND'S DISEASE (1995) (1)
Bendamustine in Chronic Lymphocytic Leukemia (CLL): Outcome According to Different Clinical and Biological Prognostic Factors in Everyday Practice (2012) (1)
Comparison of the Effects of the Thrombopoietin (TPO) Receptor Agonist Romiplostim in Patients with Immune Thrombocytopenia (ITP) for ≤1 Year Vs. >1 Year (2017) (1)
Immune thrombocytopenia in myeloid and lymphoid clonal disorders: an intriguing association (2021) (1)
Recent progress in ITP treatment (2023) (1)
Inhibitor development: The last enemy to be defeated in hemophilia A and B (2014) (1)
Health-Related Quality of Life in Patients with Primary Immune Thrombocytopenia (pITP): Investigating Differences Amongst Newly Diagnosed, Persistent and Chronic Pitp Patients (2015) (1)
Two families with combined homozygous/heterozygous factor V Leiden mutation and heterozygous G20210A factor II variant. (2000) (1)
PF695 ELTROMBOPAG AS SECOND LINE THERAPY IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ATTEMPT TO TREATMENT-FREE REMISSION. UPDATED RESULTS OF A PHASE II PROSPECTIVE STUDY BY GIMEMA GROUP (2019) (1)
Comorbidity Index: a prospective, multicenter GITMO study Validation of the Hematopoietic Cell Transplantation-Specific (2012) (1)
Chapter 8. Von Willebrand Disease (2010) (1)
Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+-CML (2014) (1)
based on the analysis of 68 cases The spectrum of Evans syndrome in adults: new insight into the disease (2012) (1)
One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients – EudraCT Number 2007–005102-42, ClinicalTrials.Gov NCT 00858806. (2010) (1)
Safety of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study (2014) (1)
Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy. (2008) (1)
Immune thrombocytopenic purpura: terminology and definitions (2009) (1)
TREATMENT OF DIC ASSOCIATED WITH APL. RESPONSE (1990) (1)
Risk Factors for Thrombosis Among 1,545 Patients with Polycythemia Vera: An International Study. (2012) (1)
Pooled Analysis of Safety and Efficacy of Romiplostim in Splenectomized and Nonsplenectomized Patients (pts) with Immune Thrombocytopenia (ITP) (2014) (1)
Failure to measure plasma activated factor XIII during disseminated intravascular coagulation (1981) (1)
BLEEDING TIME IN NORMAL SUBJECTS: ITS RELATIONSHIP WITH SEX, AGE, BLOOD GROUP, HEMATOCRIT, PLATELET COUNT AND PLASMA VON WILLEBRAND FACTOR LEVEL (1987) (1)
MCMDM-1VWD study diagnosed with type 1 von Willebrand disease in the European variant in a patient 12 Identification and characterization of a novel P2Y (2012) (1)
Juvenile essential thrombocythemia: really a benign disease? (1989) (1)
Clinical Features and Outcome of 147 Patients with Diffuse Large B-Cell Lymphoma and Hepatitis C Virus Infection. (2005) (0)
PRE-FINAL ANALYSIS OF THE PHASE II EXPLORATIVE STUDY OF INTERMITTENT IMATINIB (IM) TREATMENT (INTERIM) IN ELDERLY PH+ CML PATIENTS WITH STABLE COMPLETE CYTOGENETIC RESPONSE (CCGR) – EUDRACT NUMBER 2007-005102-42, CLINICALTRIALS.GOV NCT 00858806. (2010) (0)
[Essential thrombocythemia: clinical aspects]. (1991) (0)
Inherited thrombophilic syndromes: Experience of a department of hematology (1993) (0)
Cerebral microbleeds in ITP: alarming or innocent? (2020) (0)
disease Epidemiological investigation of the prevalence of von Willebrand's (2011) (0)
theorem approach Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes (2009) (0)
A BAYESIAN APPROACH TO THE DIAGNOSIS OF TYPE 1 VON WILLEBRAND DISEASE (2007) (0)
Immune Thrombocyt openia in Lymphoproliferative Disorders (2009) (0)
Registries in immune thrombocytopenia (ITP) in Europe: the European Research Consortium on ITP (ERCI) network (2022) (0)
C3-Mediated Extravascular Hemolysis as Additional Mechanism of Disease in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated by the Complent Inhibitor Eculizumab (2008) (0)
An Reduced Plasma Membrane Ca 2+ -atpase Function in Platelets from Patients with Non-insulin-dependent Diabetes Mellitus Letters to the Editor (0)
Multicenter Evaluation of a New Concentrated Desmopressin Preparation (Emosint) Administered Intravenously or Subcutaneously: Analysis of Biological Responses and Side-Effects in 49 Patients with Hemophilia a and Von Willebrand’s Disease (1993) (0)
Fast production of human platelet lysate by platelet rich plasma sonication for the ex-vivo expansion of bone marrow-derived mesenchymal stromal cells (2014) (0)
The Ex-Vivo Expansion of Cytokine Induced Killer (CIK) Cells Can Be Optimized Predicting Cell Expansion Dynamics by Means of Multivariate Statistical Data Analysis (2012) (0)
Immune Thrombocytopenia Associated to Low-Dose Alemtuzumab Therapy in Chronic Lymphocytic Leukemia: A Single Retrospective Center Experience (2012) (0)
Brief communication Erythroleukaemia, diabetes insipidus and hypophyseal damage: Two case reports (2007) (0)
Nationwide Survey on the Use of Thrombopoietin Receptor Agonists (TPO-RA) for the Management of Immune Thrombocytopenia in Current Clinical Practice in Italy (2023) (0)
THROMBOSIS AND HEMOSTASIS VWF propeptide and ratios between VWF , VWF propeptide , and FVIII in the characterization of type 1 von Willebrand disease (2013) (0)
Remembering Professor Roberto Stasi (August 24th 1961 – January 28th 2014) (2014) (0)
Autoimmune Thrombocytopenic Purpura Complicating Chronic Lymphocytic Leukemia: Analysis of 60 Patients. (2006) (0)
Intrinsic and method-induced variation of the bleeding time and related parameters (2007) (0)
The expert in hemostasis and thrombosis in the Italian health system: role and requirements for a specific clinical and laboratory expertise (2013) (0)
Clinical Efficacy of Desmopressin and Consistency of Responses to Separate Infusion in Patients with Prolonged Bleeding time Due to Congenital Platelet Defect (1993) (0)
Generation of mesenchymal stromal cells from cord blood: evaluation of in vitro quality parameters prior to clinical use (2017) (0)
Leucocytosis is a risk factor for recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia (2009) (0)
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting (2018) (0)
Fall Off of Factor VIII Elicited by Desmopressin Administration in Hemophiliacs and von Willebrand’s Disease Patients (1993) (0)
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients (2015) (0)
Vascular complications of endothelium targeting therapies (2009) (0)
Acute Leukemias Prognostic significance of CD56 antigen expression in acute myeloid leukemia (2002) (0)
Real-Life Management of Immune Thrombocytopenia in the Elderly: A Multicentre Study on 526 Patients (2018) (0)
Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year (2011) (0)
Unexpectedly High Incidence of Interstitial Pneumonia in Newly Diagnosed Diffuse Large B-Cell Lymphoma Treated with Rituximab-CHOP-14 Supported with Pegfilgrastim. (2005) (0)
von Willebrand's disease and hemophilia A Consistency of responses to repeated DDAVP infusions in patients with (2011) (0)
Author ' s personal copy ImmuneThrombocytopenia in Lymphoproliferative (2009) (0)
Multicenter Italian Study on Subcutaneous Concentrated Desmopressin (Emosint) for the in-Hospital and Home Treatment of Patients with von Willebrand Disease and Mild or Moderate Hemophilia A: Outline of the Project (1993) (0)
Preliminary characterization of a new congenital hypodysfibrinogenemia (vicenza II) and of dysfibrinogenemia genova IV (1993) (0)
Laboratory issues in bleeding disorders (2008) (0)
an international working group immune thrombocytopenic purpura of adults and children: report from Standardization of terminology, definitions and outcome criteria in (2009) (0)
AML-M6 Associated with Diabetes Insipidus: Potential Role of Hypophyseal Dysfunction, Monosomy-7 and Impairment of TGF-β1 Signaling in Erythroleukemogenesis. (2004) (0)
[Tooth extractions in patients with hemophilia and von Willebrand's disease]. (1987) (0)
Risk Factors for Thrombosis in WHO-Defined Early/Prefibrotic Myelofibrosis: An International Study of 264 Patients, (2011) (0)
SSC 2014 Milwaukee – Meeting Minutes (2014) (0)
Sensitivity and Specificity of Laboratory Parameters to Detect Early/Prefibrotic Myelofibrosis in 857 Patients with Essential Thrombocythemia. A Diagnostic Algorithm (2011) (0)
Recurrent Venous Thrombosis in Patients with Polycythemia Vera and Essential Thrombocythemia (2007) (0)
High Response Rate with Favorable Survival Projections in High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving R-CHOP-14 or Early Intensified Chemotherapy with Rituximab and Autograft (R-HDS): Results of the Interim Analysis of A GITIL Prospective Multicenter Phase III Study. (2009) (0)
P-07 FREEZING/THAWING CYCLES OF DONOR PLATELET APHERESIS PRODUCE VARIABLE LEVELS OF GROWTH FACTORS IN HUMAN PLATELET LYSATE (2012) (0)
Subunit S and A Ratio in Congenital and Acquired Deficiency of Factor XIII (1979) (0)
The revival of clinical wisdom: The case of oral anticoagulation management (2009) (0)
Use of DDAVP (2000) (0)
First factor IX mutations in Albanian hemophilia B patients (2008) (0)
HOMOZYGOSITY FOR JAK2V617F IDENTIFIES MPD PATIENTS WITH A MORE SYMPTOMATIC DISEASE A RETROSPECTIVE STUDY ON 989 PATIENTS FROM THE GIMEMA-MPD WORKING PARTY (2006) (0)
Introduction to a review series on the treatment of thrombocytopenic disorders: something old, something new (2022) (0)
Desmopressin-induced thrombocytopenia in von Willebrand disease patients with the Arg611His mutation in the A1 domain of von Willebrand factor. (1996) (0)
MCMDM-1 VWD study diagnosed with type 1 von Willebrand disease in the European variant in a patient 12 Identification and characterization of a novel P 2 Y (2009) (0)
von Willebrand Factor: A Prima Ballerina on Two Different Stages P.M. Mannucci New Perspectives on von Willebrand Factor Functions in Hemostasis and Thrombosis (2005) (0)
Mesenchymal stromal cells from umbilical cord blood: improving in vitro selection and characterization for clinical use (2015) (0)
lymphocytic leukemia Impact of immune thrombocytopenia on the clinical course of chronic (2008) (0)
PF696 SAFETY AND EFFICACY OF SELF-ADMINISTERED ROMIPLOSTIM IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP): RESULTS OF AN INTEGRATED ANALYSIS OF FIVE CLINICAL TRIALS (2019) (0)
Von Willebrand Disease: Clinical Aspects and Practical Management (2014) (0)
Idiopathic thrombocytopenic purpura in regnancy (2009) (0)
216 - High-throughput immunophenotypic characterization of bone marrow- and cord blood-derived mesenchymal stromal cells (MSC): Common and differentially expressed markers. relevance of hematopoietic progenitor cell marker (CD143) (2017) (0)
Treatment of 49 Unrandomized Patients with Advanced Hodgkin's Disease (1983) (0)
Prospective enrollment of patients with chronic lymphocytic leukemia in a regional registry (CLL Veneto): how unselected patients present to our center (2011) (0)
‘Reply to Pitiot et al.’ (2007) (0)
Blastic plasmacytoid dendritic cell leukemia: preliminary results of a retrospective italian multicentric study. (2011) (0)
B-cell Receptors Lymphocytic Leukemia Is Associated with Stereotyped Immune Thrombocytopenia in Patients with Chronic Updated (2012) (0)
Economic Assessment of Eltrombopag In The Treatment of Thrombocytopenia In Italy. (2015) (0)
Clinical, Laboratory, and Molecular Markers of Type 1 von Willebrand Disease (2011) (0)
Early stage gastric malt lymphoma treated with antibiotic therapy: A single institution experience (2005) (0)
Immune (Idiopathic) Thrombocytopenic Purpura (ITP): Treatment Pattern and Splenectomy Rate from a Multinational Prospective Observational Study (2008) (0)
(IPSET-thrombosis) essential thrombocythemia - thrombosis in World Health Organization Development and validation of an International Prognostic Score of (2013) (0)
thrombocythemia: a retrospective survey Post-surgery outcomes in patients with polycythemia vera and essential (2013) (0)
High-throughput immunophenotypic characterization of bone marrow- and cord blood-derived mesenchymal stromal cells reveals common and differentially expressed markers: identification of angiotensin-converting enzyme (CD143) as a marker differentially expressed between adult and perinatal tissue sour (2018) (0)
A Two-Year Prospective Study on Bleeding Tendency In 105 Patients with Type 2 A and M Von Willebrand Disease (2010) (0)
Immunochemical characterization of an acquired inhibitor to FXIII (1992) (0)
Evaluation of non-relapse mortality risk in hematopoietic stem cell transplantation; usefulness of the pretransplant scoring systems (2014) (0)
Management of paroxysmal nocturnal haemoglobinuria in the eculizumab era: the bedside and beyond (2008) (0)
FIBRINOGEN GENOVA III: A NEW CONGENITAL DYSFIBRINOGENEMIA WITH BLEEDING DIATHESIS AND DEFECTIVE LYSIS BY PLASMIN (1987) (0)
Predictors of Outcome and Response to Therapy in Primary Autoimmune Hemolytic Anemia: A Gimema Study of 307 Patients (2014) (0)
EFFECTIVENESS OF DDAVP IN PATIENTS WITH VON WILLEBRAND'S DISEASE WITH SEVERELY REDUCED BASAL LEVEL OF F VIII/VWF AND NORMAL PLATELET CONTENT(TYPE I, PLATELET NORMAL) UNDERGOING TOOTH EXTRACTION (1987) (0)
Authors' reply (1994) (0)
3.20 Stereotyped B-Cell Receptor is Associated with Immune Thrombocytopenia in CLL (2011) (0)
What's ahead in the treatment of hemophilia (2018) (0)
Salvage Therapy for Resistant or Relapsing Acute Lymphoblastic Leukemia (ALL) after Idarubicin-Based Induction (2003) (0)
Absence of micronucleus formation in cho-k1 cells cultivated in platelet lysate enriched medium produced by sonication of human platelet rich plasma (2014) (0)
Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) in Italy: A Subanalysis of the Stratus Trial (MM-010) (2015) (0)
Jak2 Exon 12 Mutational Status in a Cohort of Idiopathic Erithrocytosis V617F Negative Patients. (2007) (0)
BSH 2023 Oral abstracts book (2023) (0)
How I treat How I treat von Willebrand disease (2009) (0)
Serum Concentrations of Vitamin B-12 and Alkaline Phosphatase in Newly Diagnosed Multiple Myeloma Patients. (2005) (0)
HOMOZYGOUS FACTOR XII CONGENITAL DEFICIENCY: STUDY OF 10 NEW FAMILIES. (1987) (0)
Clotting system activation in patients with cancer undergoing major surgery: The role of heparin prophylaxis (1992) (0)
Factor XIII deficiency type I: some unresolved issues (1992) (0)
A Poor Response to Desmopressin Is Observed in Patients with Mild Hemophilia a and No Detectable FVIII Mutation. (2008) (0)
Production of human platelet lysate by soni-cation of platelet rich plasma (2013) (0)
Health-Related Quality of Life in Patients with Primary Immune Thrombocytopenia Compared with the General Population (2012) (0)
von Willebrand Disease "Vicenza" With Larger-Than-Normal (Supranormal) von (2016) (0)
Abstract (2003) (0)
Survival and outcome data observed in 98 patients affected by acute myeloid leukemia undergoing chemotherapy consolidation courses treatment followed by autologous bone marrow transplantation (auto-BMT). (2016) (0)
The cytotoxicity of cytokine induced killer cells seems to be independent by lytic degranulation and is fully retained by the CD56+ cell fraction (2014) (0)
Fatigue in long-term survivors of acute promyelocytic leukemia (APL) and its association with other symptoms and functional limitations. (2019) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Francesco Rodeghiero?

Francesco Rodeghiero is affiliated with the following schools:

Francesco Rodeghiero's Academic­Influence.com Rankings

Francesco Rodeghiero's Degrees

Similar Degrees You Can Earn

Why Is Francesco Rodeghiero Influential?

Francesco Rodeghiero's Published Works

Published Works

What Schools Are Affiliated With Francesco Rodeghiero?

Francesco Rodeghiero's AcademicInfluence.com Rankings